- Trials with a EudraCT protocol (67)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
67 result(s) found for: Drug discovery.
Displaying page 1 of 4.
EudraCT Number: 2011-001783-21 | Sponsor Protocol Number: 3288 | Start Date*: 2012-07-11 | |||||||||||
Sponsor Name:Childrens's Research Institute | |||||||||||||
Full Title: Optimizing Pain Treatment in Pre-Term Neonates | |||||||||||||
Medical condition: Critically Ill Premature Neonates between 23 and 32 weeks of gestation who are receiving morphine as part of their routine medical management of pain or other medically indicated condition for whic... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000586-19 | Sponsor Protocol Number: 307971 | Start Date*: 2005-07-25 |
Sponsor Name:Bayer Schering Pharma AG | ||
Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC) | ||
Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-021951-26 | Sponsor Protocol Number: UoL000621/R&D3963 | Start Date*: 2011-04-15 | |||||||||||
Sponsor Name:University of Liverpool [...] | |||||||||||||
Full Title: VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or m... | |||||||||||||
Medical condition: Locally advanced or metastatic pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003812-19 | Sponsor Protocol Number: ZPL389/102 | Start Date*: 2015-12-07 | |||||||||||
Sponsor Name:Ziarco Pharma Ltd | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF ONCE DAILY ORAL ZPL-3893787-18 (30 MG) ADMINISTERED FOR 12 WEEKS IN ADULT ... | |||||||||||||
Medical condition: PLAQUE PSORIASIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003471-34 | Sponsor Protocol Number: REN001-202 | Start Date*: 2022-04-19 | |||||||||||
Sponsor Name:Reneo Pharma Ltd. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF REN001 IN SUBJECTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM) | |||||||||||||
Medical condition: Primary Mitochondrial Myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) HU (Prematurely Ended) NL (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000936-23 | Sponsor Protocol Number: C20-15 | Start Date*: 2020-03-09 |
Sponsor Name:INSERM | ||
Full Title: Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults | ||
Medical condition: COVID-19 - Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 72 hours prior to randomization. - Illness of any durat... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) BE (Completed) AT (Completed) PT (Completed) SK (Completed) CZ (Completed) NO (Prematurely Ended) IE (Prematurely Ended) HU (Completed) ES (Ongoing) GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002797-23 | Sponsor Protocol Number: 11-PIR-09 | Start Date*: 2011-07-26 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY OF NKTR-102 IN SUBJECTS PREVIOUSLY ENROLLED IN NKTR-102 STUDIES | |||||||||||||
Medical condition: Solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002121-35 | Sponsor Protocol Number: GS-US-337-1406 | Start Date*: 2014-10-29 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients with Chroni... | |||||||||||||
Medical condition: Chronic Genotype 1 and Genotype 4 Hepatitis C Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009372-13 | Sponsor Protocol Number: 2009-01b | Start Date*: 2009-11-03 |
Sponsor Name:Institut de Cancérologie de la Loire | ||
Full Title: A phase II, multi-center, open-label, repeat-dose study of Lenalidomide (Revlimid ®) plus low-dose Dexamethasone in patients with refractory B-cell lineage acute lymphoblastic leukemia or in relaps... | ||
Medical condition: Treatment for B-cell Acute lymphoblastic leukemia in relapse. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023355-29 | Sponsor Protocol Number: PO1425 | Start Date*: 2011-05-18 | |||||||||||
Sponsor Name:Papworth Hospital NHS Foundation Trust | |||||||||||||
Full Title: Tyrosine kinase Inhibitors in DysplAsia of Lung epithelium Study 1 | |||||||||||||
Medical condition: High grade dysplasia of the bronchoepithelium | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002206-20 | Sponsor Protocol Number: MK-3475-052 | Start Date*: 2014-12-22 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer | |||||||||||||
Medical condition: advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DK (Completed) IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000658-27 | Sponsor Protocol Number: D5130C05262 | Start Date*: 2006-12-12 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute C... | |||||||||||||
Medical condition: non-ST and ST elevation acute coronary syndromes (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) PT (Completed) HU (Completed) DE (Completed) FR (Completed) SE (Completed) AT (Completed) NL (Completed) DK (Completed) SK (Completed) BE (Completed) CZ (Completed) GR (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001343-55 | Sponsor Protocol Number: A6061030 | Start Date*: 2006-08-02 | |||||||||||
Sponsor Name:Pfizer, S.A. | |||||||||||||
Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN). | |||||||||||||
Medical condition: Postherpetic neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Prematurely Ended) GB (Completed) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003446-45 | Sponsor Protocol Number: TBTCS31/A5349 | Start Date*: 2016-02-25 |
Sponsor Name:Unidad de investigación en Tuberculosis de Barcelona | ||
Full Title: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial | ||
Medical condition: Pulmonary tuberculosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003387-43 | Sponsor Protocol Number: GS-US-337-0102 | Start Date*: 2013-01-31 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects ... | |||||||||||||
Medical condition: Chronic Genotype 1 Hepatitis C Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005216-28 | Sponsor Protocol Number: VNK115640 | Start Date*: 2012-04-05 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 3... | |||||||||||||
Medical condition: Post-operative nausea and vomiting (PONV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003712-23 | Sponsor Protocol Number: CLAF237A23156 | Start Date*: 2012-03-14 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) FI (Completed) LV (Completed) IT (Completed) HU (Completed) DE (Completed) EE (Completed) SK (Completed) BG (Completed) PL (Completed) NO (Completed) CZ (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016266-90 | Sponsor Protocol Number: EFC11072 | Start Date*: 2011-05-03 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: Estudio aleatorizado, doble-ciego, controlado con placebo, multicéntrico, de dos partes, de búsqueda de dosis y confirmatorio, con un diseño operacionalmente adaptativo que evalúa la eficacia y seg... | |||||||||||||
Medical condition: Artritis Reumatoide _____________________________________ Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) FI (Completed) HU (Completed) EE (Completed) DE (Completed) LT (Completed) PT (Completed) NL (Completed) GR (Completed) RO (Completed) AT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001714-96 | Sponsor Protocol Number: R2222-RSV-1332 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in ... | |||||||||||||
Medical condition: Medically attended respiratory syncytial virus infection | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) HU (Completed) FI (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000376-26 | Sponsor Protocol Number: ZPL521/101 | Start Date*: 2016-05-09 | |||||||||||
Sponsor Name:Ziarco Pharma Ltd | |||||||||||||
Full Title: A Randomised, Adaptive Design, Double-Blind (3rd Party Open), Placebo Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Applica... | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
